Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Mai 2022 08:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Three SNK01 Abstracts to be Presented at the 2022 ASCO Annual Meeting

SANTA ANA, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech Inc., a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
15. November 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

SANTA ANA, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a subsidiary of NKMax, harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
20. Oktober 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting

SANTA ANA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
07. Oktober 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO

SANTA ANA, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
04. Oktober 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
15. April 2021 08:30 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer

SANTA ANA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
13. April 2021 09:30 ET | Quelle: NKGen Biotech, Inc.

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
07. April 2021 09:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer

SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
02. April 2021 06:30 ET | Quelle: NKGen Biotech, Inc.

NKMax America Announces Corporate Name Change to NKGen Biotech

SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
04. Februar 2021 08:00 ET | Quelle: NKMax America

NKMax America Announces Key Leadership Appointment

SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...

Vorherige Seite

Nächste Seite